These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3126101)

  • 1. Treatment for the myelodysplastic syndromes.
    Jacobs A
    Haematologica; 1987; 72(6):477-80. PubMed ID: 3126101
    [No Abstract]   [Full Text] [Related]  

  • 2. [Myelodysplastic syndromes].
    Guisasola Zulueta MC; Gilsanz Fernández C; Tintó del Val JA; García de la Fuente A
    Rev Clin Esp; 1986 Sep; 179(4):190-5. PubMed ID: 3764008
    [No Abstract]   [Full Text] [Related]  

  • 3. Differentiation-inducing agents in the treatment of myelodysplastic syndromes.
    Kizaki M; Koeffler HP
    Semin Oncol; 1992 Feb; 19(1):95-105. PubMed ID: 1371019
    [No Abstract]   [Full Text] [Related]  

  • 4. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
    Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P
    J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
    García Marco J; Miguel Sosa A; García Conde J; Miguel García A; Arbona C; Escrig V; Benet I; Navarro I; Ruiz A; Carbonell F
    Sangre (Barc); 1994 Aug; 39(4):241-4. PubMed ID: 7985051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation therapy in myelodysplastic syndromes.
    Morosetti R; Koeffler HP
    Semin Hematol; 1996 Jul; 33(3):236-45. PubMed ID: 8819233
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of patients with myelodysplastic syndromes: a review.
    Tricot G; Boogaerts MA; Verwilghen RL
    Scand J Haematol Suppl; 1986; 45():121-7. PubMed ID: 3515516
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of hematologic disorders using a metabolite of vitamin D].
    Wilczek H; Neuwirtová R; Pacovský V
    Cas Lek Cesk; 1986 Oct; 125(40):1235-8. PubMed ID: 3779773
    [No Abstract]   [Full Text] [Related]  

  • 9. [A therapeutic trial with low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a study of 15 cases].
    Maruta A; Miyashita H; Kodama F; Harano H; Kanamori H; Takahashi K; Noguchi T; Matsuzaki M; Ogawa K; Motomura S
    Rinsho Ketsueki; 1988 Jan; 29(1):8-13. PubMed ID: 3385938
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic factors and treatment of myelodysplastic syndromes.
    Mijović A; Bosković D; Elezović I; Tomin D; Gotić M; Janosević S; Rolović Z
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():61. PubMed ID: 2697404
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-dose cytosine arabinoside in myelodysplastic syndromes.
    Mineur P; Martiat P; Ferrant A; Michaux JL
    Acta Clin Belg; 1989; 44(1):62-3. PubMed ID: 2763785
    [No Abstract]   [Full Text] [Related]  

  • 12. [All-trans-retinoic acid in the differential therapy of proliferative hemocytic diseases. I. Properties of biological retinoids].
    Skotnicki AB; Sledziowski P; Sacha T; Jurczak W
    Przegl Lek; 1995; 52(1):31-4. PubMed ID: 7784610
    [No Abstract]   [Full Text] [Related]  

  • 13. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome.
    Ferrero D; Campa E; Dellacasa C; Campana S; Foli C; Boccadoro M
    Haematologica; 2004 May; 89(5):619-20. PubMed ID: 15136232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [All-trans-retinoic acid in differentiation therapy of hemo-cytopathic proliferative diseases. II. Retinoids in clinical practice].
    Skotnicki AB; Sledziowski P; Sacha T; Jurczak W
    Przegl Lek; 1995; 52(4):145-6. PubMed ID: 7638362
    [No Abstract]   [Full Text] [Related]  

  • 15. Calcitriol in myelodysplastic syndromes.
    Howard MR; Bond LR
    Br J Haematol; 1999 Aug; 106(2):572-3. PubMed ID: 10460627
    [No Abstract]   [Full Text] [Related]  

  • 16. [Experiences with low-dos Ara-C in the therapy of hematological neoplasms].
    Jacky E; Frick P
    Ther Umsch; 1988 Feb; 45(2):119-23. PubMed ID: 3358244
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment for myelodysplastic syndromes.
    Lancet; 1987 Sep; 2(8561):717-9. PubMed ID: 2888944
    [No Abstract]   [Full Text] [Related]  

  • 18. The myelodysplastic syndromes.
    Jacobs A
    Br Med J (Clin Res Ed); 1987 Aug; 295(6597):553-4. PubMed ID: 3117223
    [No Abstract]   [Full Text] [Related]  

  • 19. 13-cis-retinoic acid in myelodysplastic syndromes.
    Greenberg BR; Buzaid AC; Meyskens FL
    J Clin Oncol; 1986 Aug; 4(8):1282. PubMed ID: 3525772
    [No Abstract]   [Full Text] [Related]  

  • 20. [Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine].
    Waage A; Hammerstrøm J; Lødemel B; Hoff JE; Langtind J
    Tidsskr Nor Laegeforen; 1986 Feb; 106(6):496-7. PubMed ID: 3457484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.